Title: Reduction by dietary matrix metalloproteinase inhibitor BAY 12-9566N of neoplastic development induced by diethylnitrosamine, N-nitrosodimethylamine, or 7,12-dimethylbenz(a)anthracene in rats.
Journal: Drug and chemical toxicology 20080101
Title: Neutralization of the haemorrhagic activities of viperine snake venoms and venom metalloproteinases using synthetic peptide inhibitors and chelators.
Journal: Toxicon : official journal of the International Society on Toxinology 20070401
Title: Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study.
Journal: Journal of veterinary internal medicine 20070101
Title: A phase III randomized trial of BAY 12-9566 (tanomastat) as maintenance therapy in patients with advanced ovarian cancer responsive to primary surgery and paclitaxel/platinum containing chemotherapy: a National Cancer Institute of Canada Clinical Trials Group Study.
Journal: Gynecologic oncology 20060801
Title: Recent advances in MMP inhibitor design.
Journal: Cancer metastasis reviews 20060301
Title: A phase I and pharmacokinetic study of the selective, non-peptidic inhibitor of matrix metalloproteinase BAY 12-9566 in combination with etoposide and carboplatin.
Journal: Anti-cancer drugs 20051001
Title: Inhibition of matrix metalloproteinases during chronic allograft nephropathy in rats.
Journal: Transplantation 20050327
Title: An NCIC CTG phase I/pharmacokinetic study of the matrix metalloproteinase and angiogenesis inhibitor BAY 12-9566 in combination with 5-fluorouracil/leucovorin.
Journal: Investigational new drugs 20050101
Title: [Expression of matrix metalloproteinases in patients with malignant tumors].
Journal: Medicina (Kaunas, Lithuania) 20040101
Title: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20030901
Title: [Adjuvant treatment of pancreatic cancer].
Journal: Zentralblatt fur Chirurgie 20030501
Title: Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancer orthotopic model.
Journal: Clinical & experimental metastasis 20030101
Title: Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Journal: Seminars in oncology 20021201
Title: Clinical trial designs for targeted agents.
Journal: Hematology/oncology clinics of North America 20021001
Title: Phenoxyphenyl sulfone N-formylhydroxylamines (retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors.
Journal: Journal of medicinal chemistry 20020103
Title: Mechanism for further enhancement in drug dissolution from solid-dispersion granules upon storage.
Journal: Pharmaceutical development and technology 20020101
Title: Enhanced drug dissolution and bulk properties of solid dispersions granulated with a surface adsorbent.
Journal: Pharmaceutical development and technology 20011101
Title: Pharmacokinetics, safety, and tolerability of BAY 12-9566 and nonsteroidal anti-inflammatory agents (naproxen, ibuprofen) during coadministration in patients with osteoarthritis.
Journal: Journal of clinical pharmacology 20010301
Title: Development of matrix metalloproteinase inhibitors in cancer therapy.
Journal: Journal of the National Cancer Institute 20010207
Title: Protease inhibitors: current status and future prospects.
Journal: Journal of medicinal chemistry 20000210
Title: Leung D, et al. Protease inhibitors: current status and future prospects. J Med Chem. 2000 Feb 10;43(3):305-41.
Title: Gatto C, et al. BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res. 1999 Nov;5(11):3603-7.
Title: Nozaki S, et al. Activity of biphenyl matrix metalloproteinase inhibitor BAY 12-9566 in a human breast cancerorthotopic model. Clin Exp Metastasis. 2003;20(5):407-12.
